Breaking News
Get 45% Off 0
Is it finally time to sell Nvidia ahead of earnings?
Read More

Breaking News

U.S. stocks mixed as caution persists prior to Nvidia earnings

Ionis (IONS) Beats Both Earnings & Revenues In Q4

By Zacks Investment ResearchStock MarketsFeb 26, 2018 08:43PM ET
www.investing.com/analysis/ionis-ions-beats-both-earnings--revenues-in-q4-200294635
Ionis (IONS) Beats Both Earnings & Revenues In Q4
By Zacks Investment Research   |  Feb 26, 2018 08:43PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
BIIB
+2.56%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
FMC
+0.75%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
IONS
-1.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen (NASDAQ:BIIB) and GlaxoSmithKline among others.

In this quarter, the company received $115.7 million in upfront fees and milestone payments from its partners. Also, regulatory applications for approval of volanesorsen and Inotersen are under review in the United States and EU.

Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 6.67%, missing estimates in two quarters and beating the same once.

Currently, Ionis has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Ionis reported an earnings of 2 cents including stock based compensation which beat the Zacks Consensus Estimate of loss of 8 cents.

Revenues: Ionis posted revenues of $172.3 million, beating the consensus estimate of $115.44 million.

Key Stats: Research, development and patent expenses amounted to $128.3 million, up 26.8% year over year. General and administrative expenses increased almost 153% year over year to $45.7 million on increased costs related to commercialization of volanesorsen and inotersen, and increase in fees related to in-licensing of Spinraza. Spinraza saw strong uptake in full year 2017 with $884 million in sales.

2018 Outlook: The company expects the R&D expenses to be in the range of $360 million - $390 million, while SG&A expenses are expected in the range of $180 million - $210 million. Ionis also plans to launch inotersen and volanesorsen in 2018.

Share Market Activity: Share price are down 0.2% in pre-market trading.

Zacks Top 10 Stocks for 2018

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?

Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp (NYSE:FMC). and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2018 today >>



Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report

Original post

Ionis (IONS) Beats Both Earnings & Revenues In Q4
 

Related Articles

Ionis (IONS) Beats Both Earnings & Revenues In Q4

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email